The approval allows treatment of heart failure patients irrespective of the ejection fraction based on new trial DELIVER conducted by AstraZeneca AstraZeneca Pharma India Ltd. (AstraZeneca India), a science-led biopharmaceutical company, announced it has received extended indication approval from the Drugs Controller General of India
Tremelimumab in combination with Durvalumab is indicated for the treatment of patients with unresectable hepatocellular carcinoma (uHCC) AstraZeneca Pharma India Ltd. (AstraZeneca India), a science-led biopharmaceutical company, announced it has received approval from the Central Drugs Standard Control Organisation (CDSCO) for its cancer drug Tremelimumab Concentrate
Dapagliflozin reduces the risk of sustained eGFR, cardiovascular deaths and hospitalization for heart failure in adults with CKD Indicated in adults for the treatment of patients of Chronic Kidney Disease up to eGFR greater than or equal to 25 ml per min per 1.73 m2 AstraZeneca
Results presented at European Society of Cardiology Congress 2022, and published in New England Journal of Medicine Data extend the clinically meaningful benefits of dapagliflozin in patients with heart failure regardless of ejection fraction Heart failure is a chronic, progressive disease impacting nearly 64
This is the second such camp under AstraZeneca India’s Ganga Godavari Cancer Screening Programme, which aims to spread awareness and facilitate early detection of Oral, Breast, and Cervical Cancers at early stages among women. AstraZeneca India (AstraZeneca Pharma India Limited), a leading science-led biopharmaceutical company,
